EVO — Evotec SE
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1412558 ·
Germany
Last close
$1.57
Market Cap
$557.96M
52W High
$4.27
52W Low
$1.50
ADV30
144,826
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 143,479,000 | -1,579,000 | -89,322,000 | -46,649,000 | 1,573,975,000 | 348,356,000 | 908,397,000 |
| Mar 2026 | 156,644,000 | -1,569,000 | -46,423,000 | -121,936,000 | 1,639,812,000 | 387,912,000 | 940,192,000 |
| Dec 2025 | 253,273,000 | 78,463,000 | 37,208,000 | 14,624,000 | 1,713,945,000 | 401,786,000 | 900,241,000 |
| Sep 2025 | 163,887,000 | -62,000 | -44,610,000 | -43,087,000 | 1,772,700,000 | 174,038,000 | 972,564,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$18,709,000
Investing CF
$180,760,000
Financing CF
$-92,147,000
CapEx
$-71,572,000
Dividends Paid
$0
Buybacks
—
EPS Diluted TTM
$-0.68
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-897,823,000
Inventory
$32,982,000
Receivables
$167,051,000
ST Investments
$75,871,000
EBIT TTM
$-164,477,000
Pretax Income TTM
$-179,095,000
Interest Exp TTM
$14,618,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$717,283,008
EBITDA
$-73,181,000
Free Cash Flow
$-80,990,624
Enterprise Value
$625,030,208
Total Cash
$465,587,008
Total Debt
$475,865,984
Shares Out
355,389,118
Trailing EPS
$-0.65
Book Value
$2.17
ROE
-26.1%
ROA
-5.4%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 788,373,000 | -55,818,000 | -103,517,000 | 1,713,945,000 | 900,241,000 | 813,704,000 | -9,179,000 |
| Dec 2024 | 796,967,000 | -78,919,000 | -196,078,000 | 1,912,502,000 | 959,977,000 | 952,525,000 | 18,220,000 |
| Dec 2023 | 781,426,000 | -26,628,000 | -83,913,000 | 2,252,468,000 | 1,132,560,000 | 1,119,908,000 | 36,439,000 |
| Dec 2022 | 751,448,000 | 20,850,000 | -175,655,000 | 2,257,247,000 | 1,070,063,000 | 1,187,184,000 | 205,811,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.19
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ACRS | Aclaris Therapeutics, Inc. | $557.88M | $3.79 | — |
| MNPR | Monopar Therapeutics | $563.69M | $83.98 | — |
| IMMP | IMMUTEP Ltd | $565.91M | $3.84 | — |
| SGMT | Sagimet Biosciences Inc. | $549.39M | $8.92 | — |
| STTK | Shattuck Labs, Inc. | $568.06M | $5.66 | — |
News headlines (Yahoo Finance, 1h cache)
4BIO Capital leads €40 Million ($45M) seed financing of Aptadir Therapeutics to advance first-in-class demethylating medicines
2026-09-29 09:27 · Yahoo
Evotec Announces Chief Scientific Officer Transition
2026-09-29 06:04 · Yahoo
APTADIR RAISES A €40M ($45M) SEED FINANCING TO ADVANCE FIRST-IN-CLASS DEMETHYLATING MEDICINES
2026-09-29 04:00 · Yahoo
Secure the Global Drug Discovery Services Report: Capitalize on AI-driven outsourcing and benchmark Charles River, Labcorp, Evotec, WuXi AppTec and Syngene before rivals capture the next revenue wave
2026-09-24 08:02 · Yahoo
Capitalize on the In Vivo Toxicology Shake-Up: Benchmark Charles River, Labcorp, Evotec, WuXi AppTec and Thermo Fisher Before R&D Shifts Redraw Global Market Share
2026-09-23 08:10 · Yahoo
Capitalize on the Drug Discovery Outsourcing Shift: Benchmark Charles River, WuXi AppTec, Evotec, Labcorp and Sygnature to Secure R&D ROI and Outsmart the Global Market
2026-09-23 08:08 · Yahoo
Disrupt Drug Discovery and Secure R&D ROI: Benchmark Fragment-Based Strategies from Astex, Evotec, Charles River, Schrödinger and Vernalis Through 2030
2026-09-22 08:32 · Yahoo
Capitalize on Compound Management Disruption: Track Brooks Life Sciences, Tecan, Hamilton and Evotec as automation transforms R&D economics and competitive ROI
2026-09-22 08:23 · Yahoo
Just - Evotec Biologics Advances U.S. Department of War Antibodies Against Orthopoxvirus into Phase 1 Clinical Studies
2026-09-09 06:00 · Yahoo
Evotec and Plectonic Enter Research Collaboration to Explore New Generation of T-Cell-Engaging Approaches for Solid Tumors
2026-09-02 06:04 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.